Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 20121419.
- Also identified by DOI 10.1086/650539 and PMC identifier 2975665.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .
Medical subject headings
- Acquired Immunodeficiency Syndrome
- Antiviral Agents
- Benzoxazines
- Nevirapine